
Pediatric Pulmonologist

No OPD information available
Bronchitis
Cerebral Hypoxia
Infantile Apnea
Infantile Pneumothorax
Premature Infant
Infant Respiratory Distress Syndrome
Low Blood Pressure
Metabolic Acidosis
Parainfluenza
Pneumonia
Andreas Schibler is a male healthcare provider who helps patients with various respiratory and critical care conditions like bronchitis, pneumonia, and low blood pressure. He specializes in treating infants and premature babies who may have breathing difficulties or other health issues.
Schibler uses special skills and treatments to care for his patients, ensuring they receive the best possible medical attention. He communicates with patients in a kind and understanding way, which helps them feel comfortable and trust him with their care.
To stay updated with the latest medical knowledge, Schibler regularly reads research papers and attends conferences to learn about new treatments and technologies. This dedication to learning helps him provide the most effective care to his patients.
Schibler works closely with other medical professionals, collaborating with colleagues to ensure patients receive comprehensive and coordinated care. His positive relationships with fellow healthcare providers contribute to a supportive and effective working environment.
Through his work, Schibler has made a positive impact on many patients' lives by improving their health outcomes and providing compassionate care. His dedication to his patients' well-being is evident in the positive feedback and gratitude he receives from those he helps.
In addition to his clinical work, Schibler has contributed to research in the field of pediatric emergency medicine, with notable publications on topics like parental attitudes towards research consent in clinical trials. He has also been involved in clinical trials to evaluate new treatments for respiratory infections in hospitalized infants, showing his commitment to advancing medical knowledge and improving patient care.
Enrollment Status: Completed
Published: February 20, 2024
Intervention Type: Drug
Study Drug:
Study Phase: Phase 2
